What the label lists and what reports show
Adalimumab-fkjp side effects
Adalimumab-fkjp's FDA label: “Most common adverse reactions (>10%) are: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.” FAERS holds 46,053 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is fatigue (5,474 reports).
- No generic listed
- Boxed warning
Check it at the source: the adalimumab-fkjp FDA label on DailyMed (effective January 12, 2026, Biocon Biologics Inc); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of Adalimumab-fkjp?Adalimumab-fkjp can cause serious side effects, including: See “What is the most important information I should know about Adalimumab-fkjp?” • Serious Infections. Your healthcare provider will examine you for TB and perform a test to see if you have TB. If your healthcare provider feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with Adalimumab-fkjp and during treatment with Adalimumab-fkjp. Even if your TB test is negative your healthcare provider should carefully monitor you for TB infections while you are taking Adalimumab-fkjp. People who had a negative TB skin test before receiving adalimumab products have developed active TB. […]
Source: FDA drug label, BLA761154 (Mylan Pharms Inc), as published by Biocon Biologics Inc, effective January 12, 2026 (SPL set 5cde907d-6747-0e62-db25-1718ee717fe7), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (>10%) are: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.
Table 1. Adverse Reactions Reported by ≥5% of Patients Treated with Adalimumab During Placebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)
| Reaction | Adalimumab 40 mg subcutaneous Every Other Week (N=705) | Placebo (N=690) |
|---|---|---|
| Upper respiratory infection | 17% | 13% |
| Sinusitis | 11% | 9% |
| Flu syndrome | 7% | 6% |
| Nausea | 9% | 8% |
| Abdominal pain | 7% | 4% |
| Laboratory test abnormal | 8% | 7% |
| Hypercholesterolemia | 6% | 4% |
| Hyperlipidemia | 7% | 5% |
| Hematuria | 5% | 4% |
| Alkaline phosphatase increased | 5% | 3% |
| Headache | 12% | 8% |
| Rash | 12% | 6% |
| Accidental injury | 10% | 8% |
| Injection site reaction Does not include injection site erythema, itching, hemorrhage,… | 8% | 1% |
| Back pain | 6% | 4% |
| Urinary tract infection | 8% | 5% |
| Hypertension | 5% | 3% |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following clinically significant adverse reactions are described elsewhere in the labeling: • Serious Infections [see Warnings and Precautions (5.1) ] • Malignancies [see Warnings and Precautions (5.2) ] • Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] • Hepatitis B Virus Reactivation [see Warnings and Precautions (5.4) ] • Neurologic Reactions [see Warnings and Precautions (5.5) ] • Hematological Reactions [see Warnings and Precautions (5.6) ] • Heart Failure [see Warnings and Precautions (5.8) ] • Autoimmunity [see Warnings and Precautions (5.9) ] Most common adverse reactions (>10%) are: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Biocon Biologics at 1-833-986-1468 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reaction with adalimumab was injection site reactions. …
Source: FDA drug label, BLA761154 (Mylan Pharms Inc), as published by Biocon Biologics Inc, effective January 12, 2026 (SPL set 5cde907d-6747-0e62-db25-1718ee717fe7), via openFDA; the full label on DailyMed
What do FAERS reports show?
46,053 reports list adalimumab-fkjp among the medicines taken, each a report of something that happened, not proof the medicine caused it; 6,734 are coded as a death and 16,373 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2024 (8,764, against a median of 2,819 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens. Of the 20 reactions below, 8 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Adalimumab-fkjp: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions